ABSTRACT Autologous femoral vein segments were implanted as aortocoronary bypass grafts in 50 dogs, 25 of which were treated with dipyridamole and aspirin to inhibit platelet deposition and 25 that were not. Autologous platelets labeled with indium-1 1 1 were injected into some dogs 48 hr before they were killed on the first day after surgery; other dogs were injected 24 hr before they were killed (3, 7, 30, and 90 days after surgery). Radioactivity on the grafts and on control specimens of contralateral femoral veins was converted to quantification of platelets adhering to the vessel wall (platelets/cm2). The treated group had fewer graft platelets per square centimeter than the untreated group on postoperative days 3, 7 (p < .01), and 30 (p < .05). Graft and control vein platelets per square centimeter were nearly equal by day 90. Comparison of graft and control specimens by scanning electron microscopy revealed deendothelialization at 1 and 7 days after grafting and reendothelialization at 30 and 90 days. The data suggest that indefinite prolongation of therapy to inhibit platelet deposition after bypass grafting may be unnecessary (although other atherosclerotic vessels may benefit from therapy). figure 1 .
A MAJOR LIMITATION of aortocoronary bypass with autologous saphenous vein grafts is the high frequency of graft occlusion by platelet thrombosis in the early postoperative phase and by proliferation of intimal smooth-muscle cells in the late phase. All vein grafts develop some morphologic changes with time,'-" but the degree and functional significance of the changes may differ because of several factorsloss of endothelial cells during harvesting and implantation of the graft, deposition of platelets or fibrin, graft wall ischemia, intraluminal pressure, vortexing and shear stress at distal anastomoses and vein valves,7 and functional alteration and repair of damaged endothelium.3 49 During harvesting and implantation of femoral vein grafts in dogs, the grafts become partially deendothelialized (as shown by scanning electron microscopic studies); consequently graft permeability and cholesterol uptake increase. 11 From figure 1 .
Medication with dipyridamole and aspirin. The dogs were divided into two groups: 25 received no medication other than systemic antibiotics during surgery (and are called "untreated"); the other 25 were given dipyridamole, 55 mg orally, on each of the 2 days preceding surgery and then were given 55 mg of dipyridamole and 325 mg of aspirin at 1 hr after surgery and daily thereafter until they were killed.
Platelet labeling. Autologous platelets of the dogs were labeled with "'In-(tropolone)3 according to the method of Dewanjee et al. 12 , 13 In brief, platelet-rich plasma was separated from blood anticoagulated with acid citrate dextrose solution (ACD) (7:43) by centrifugation for 10 min at 180 gmaximum, The platelet pellet was obtained by centrifugation of platelet-rich plasma (1600 gmaximum for 10 min). Next, 400 to 500 ,uCi of l'In-(tropolone)3 was added to the platelet pellet suspended in 4 ml of ACD-saline. After incubation at room temperature for 20 min, unbound "'In was removed by washing with 4 ml of ACDplasma (1600 gmaxmum for 10 min Blood samples in duplicate were centrifuged to remove plasma, and the radioactivity (1 'In-cpm) in plasma was used to determine the percentage of free Iin. With that, the percentage of radioactivity bound to platelets was determined, and next the platelet-bound lIlIn-cpm/ml blood was determined:
x (100 -% free "I`n) ml blood ml blood Then, from "'In-cpm/ml of blood and the platelet count in EDTA blood, the number of platelets per cpm was calculated: No. platelets No. platelets/ml blood "'In-cpm "'In-cpm/ml blood Graft and saphenous vein. Each graft and anastomotic segment and each control vein specimen was spread on linear graph paper and outlined carefully, and its area was determined by counting the number of squares. With the data then available the area (cm2) of each segment, radioactivity (cpm) in each, and number of platelets per cpm the number of platelets adhering to each square centimeter of surface of blood vessel and anastomosis was calculated:
No. platelets l l lIn-cpm in specimen
No. platelets
The amount of free "'In in the labeled platelet preparation was in the range of 4% to 6%. The amount of free 'In in the 1 day study group was 6% to 8%; in all other study groups the level of free l in measured at 4% to 6% 24 hr after administration. figure 3 and treated in figure 4.
Significant differences between the two groups appeared at 3 days after grafting (p < .01) but not later.
Also, at day 3 within the untreated group, the radioactivity ratio of the distal segment was higher than those of the middle and proximal segments (although not significantly so), whereas within the treated group the ratios of all segments were more alike.
Response We have reported noninvasive imaging of platelet deposition in the short-term phase. Since the number of adherent platelets decreases severalfold within a short period of grafting, this imaging technique may not be applicable in the long-term phase without appropriate background subtraction.2' We did not use the subtraction technique in this study.
Our recently developed process has been applied for evaluation of drugs intended to inhibit platelet deposition in bilateral femoral vein and graft (Gore-Tex) implants in dogs.22 Electron microscopic techniques are useful in demonstrating deendothelialization and the adherence of single and multiple platelets to deendothelialized surface, but pressure-perfusion, fixation, and other manipulations involved in preparing specimens for such examination lead to loss of surface-adherent platelets and underestimation of platelet thrombosis. The radioactivity-measurement technique is useful for studying platelet thrombosis in the arterial system as well as for evaluation of platelet-inhibitor drugs in models of bilateral femoral graft implants.
Because thrombosis is a surface reaction, we think our measurements of platelet thrombosis should be expressed as the number of adherent platelets per unit of surface area. Such expression has been useful in both of our studies of platelet thrombosis in various cardiovascular prostheses and vascular grafts and of platelet inhibitors, which have been carried out in large numbers of animals and 200 human subjects. In this study, it enabled us to compare radioactivity in the graft with that in control vein specimens (figures 3 and 4), which could not be done accurately without normalization because of variation from animal to animal with respect to amount of injected radioactivity, blood volume, and platelet count. Since all the data in the control and treated groups were obtained and analyzed in the same way, they must all be affected in the same way, without lessening the validity of comparisons.
Although labeled platelets do not aggregate to the same extent as undisturbed platelets, we believe that the labeling causes only partial degranulation, rather than irreversible damage, and that they recuperate within 24 hr after administration and participate in the thrombotic process. The small number of platelet aggregates that formed were removed by centrifugation before intravenous administration. On biodistribution, performed in most of our experimental animals, less than 1.5% of total In-labeled platelets were found in the lung tissue. Furthermore, we have recently measured platelet adhesion to various synthetic graft materials by techniques using the scanning electron microscope and lIn-labeled platelets.23 The order of platelet adhesion to Dacron and Gore-Tex (Teflon) grafts and other reference materials is similar except that the tracer technique is five to 100 times more sensitive. Since platelet thrombosis is a surface reaction, we believe this interaction could be best represented by the number of adherent platelets per unit surface.
With regard to the amount of platelet deposition we 354 found on graft sections at 1 day after grafting, the insignificant difference between the control and treated groups of dogs might be due to platelet trauma during cardiopulmonary bypass and contamination of the local adventitial surface by blood oozing from the anastomosis. Clinical implications of the findings. In management of patients who have undergone aortocoronary bypass grafting, it is essential to prevent thrombotic occlusion of the graft without inducing excessive postoperative bleeding. Side effects of, variability of intolerance to, and compliance of patients to drug therapy complicate decisions as to how long the treatment should be continued drug cost also is a factor. Although the data obtained from our studies suggest that a relatively short period of therapy is necessary, the studies are limited by the use of almost healthy dogs. Their healthy coronary arteries and healthy veins might benefit less from prolonged inhibition of platelet deposition than do the diseased veins and coronary arteries of man; hence, these results may not be directly applicable to aortocoronary bypass grafting in human patients.
In man, an atherogenic diet, lipoprotein profile, rate of reendothelialization, or recurrent endothelial damage may justify use of these drugs over a long period. When the small lumen at the distal anastomoses is considered, the decision not to treat may be the riskier choice. Nevertheless, this study of the course of platelet deposition during the early and late periods after studies. The advantage of the tracer technique is that it estimates total platelet deposition over a wider surface area, whereas the electron microscope reveals only the superficial layer of platelets on a smaller selected area and underestimates the total number of platelets adhering. As the graft reendothelializes, both platelet adhesion and graft permeability to blood-borne molecules decrease and, hence, the likelihood of thrombosis and atherosclerosis decreases. Consequently, we suggest that inhibition of platelet deposition is indeed beneficial during the intraoperative and the immediate postoperative period. As reendothelialization takes place, the need for antiplatelet therapy wanes. At the time of complete reendothelialization, it should be possible to discontinue administration of antiplatelet drugs without consequent graft occlusion.
